© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 17, 2015
Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.
September 18, 2015
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).